Narrative
Aromatase inhibitors (AIs) significantly improve survival from breast cancer but are associated with increases in osteoporotic fractures and bone mineral density loss. Research at the University of Manchester (UoM) has provided key evidence that has contributed to preventing debilitating bone demineralisation safely in breast cancer patients undergoing adjuvant therapy with AIs. UoM findings have led to an international consensus on guidelines recommending Dual-energy X-ray Absorptiometry (DEXA) scanning to identify patients at risk of bone loss as well as the use of bisphosphonates where bone loss has been identified. Further guidelines advise against the use of HRT to treat bone loss as a result of its association with breast cancer recurrence| Impact date | 2014 |
|---|---|
| Category of impact | Health impacts |
| Impact level | Benefit |
Documents & Links
Related content
-
Research output
-
Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy
Research output: Contribution to journal › Article › peer-review
-
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results
Research output: Contribution to journal › Article › peer-review
-
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial
Research output: Contribution to journal › Article › peer-review
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Research output: Contribution to journal › Article › peer-review